Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3/2016

01-09-2016 | NON-THEMATIC REVIEW

The roles and implications of exosomes in sarcoma

Authors: Li Min, Jacson Shen, Chongqi Tu, Francis Hornicek, Zhenfeng Duan

Published in: Cancer and Metastasis Reviews | Issue 3/2016

Login to get access

Abstract

Better diagnostic biomarkers and therapeutic options are still necessary for patients with sarcomas due to the current limitations of diagnosis and treatment. Exosomes are small extracellular membrane vesicles that are released by various cells and are found in most body fluids. Tumor-derived exosomes have been proven to mediate tumorigenesis, intercellular communication, microenvironment modulation, and metastasis in different cancers, including in sarcomas. Recently, exosomes have been considered as potential biomarkers for sarcoma diagnosis and prognosis, and as possible targets for sarcoma therapy. Moreover, due to their specific cell tropism and bioavailability, exosomes can also be engineered as vehicles for drug delivery. In this review, we discuss recent advances in the roles of tumor-derived exosomes in sarcoma and their potential clinical applications.
Literature
1.
Riggi, N., et al. (2007). Sarcomas: genetics, signalling, and cellular origins. Part 1: the fellowship of TET. Journal of Pathology, 213(1), 4–20.PubMedCrossRef
2.
Harwood, J. L., et al. (2015). Targeted chemotherapy in bone and soft-tissue sarcoma. The Orthopedic Clinics of North America, 46(4), 587–608.PubMedCrossRef
3.
4.
Bielack, S. S., et al. (2009). Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. Journal of Clinical Oncology, 27(4), 557–565.PubMedCrossRef
5.
Benjamin, R.S., et al. (2015). Chemotherapy for bone sarcomas in adults: the MD Anderson experience. American Society of Clinical Oncology Educational Book, p. e656-60.
6.
Yakkioui, Y., et al. (2014). Chordoma: the entity. Biochimica et Biophysica Acta, 1846(2), 655–669.PubMed
7.
Johnstone, R. M., et al. (1987). Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). Journal of Biological Chemistry, 262(19), 9412–9420.PubMed
8.
Rabinowits, G., et al. (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clinical Lung Cancer, 10(1), 42–46.PubMedCrossRef
9.
Silva, J., et al. (2012). Analysis of exosome release and its prognostic value in human colorectal cancer. Genes, Chromosomes & Cancer, 51(4), 409–418.CrossRef
10.
11.
12.
13.
Ye, S. B., et al. (2014). Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget, 5(14), 5439–5452.PubMedPubMedCentralCrossRef
14.
Kim, M. S., et al. (2016). Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine, 12(3), 655–664.PubMed
15.
Rivoltini, L., et al. (2016). TNF-related apoptosis-inducing ligand (TRAIL)-armed exosomes deliver pro-apoptotic signals to tumor site. Clinical Cancer Research.
16.
17.
Cocucci, E., & Meldolesi, J. (2015). Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends in Cell Biology, 25(6), 364–372.PubMedCrossRef
18.
Minciacchi, V. R., Freeman, M. R., & Di Vizio, D. (2015). Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Seminars in Cell and Developmental Biology, 40, 41–51.PubMedPubMedCentralCrossRef
19.
van der Pol, E., et al. (2012). Classification, functions, and clinical relevance of extracellular vesicles. Pharmacological Reviews, 64(3), 676–705.PubMedCrossRef
20.
Mathivanan, S., et al. (2012). ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Research, 40(Database issue), D1241–D1244.PubMedCrossRef
21.
Baietti, M. F., et al. (2012). Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nature Cell Biology, 14(7), 677–685.PubMedCrossRef
22.
Muralidharan-Chari, V., et al. (2009). ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Current Biology, 19(22), 1875–1885.PubMedPubMedCentralCrossRef
23.
Akers, J. C., et al. (2013). Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. Journal of Neuro-Oncology, 113(1), 1–11.PubMedCrossRef
24.
Turiak, L., et al. (2011). Proteomic characterization of thymocyte-derived microvesicles and apoptotic bodies in BALB/c mice. Journal of Proteomics, 74(10), 2025–2033.PubMedCrossRef
25.
Minciacchi, V. R., et al. (2015). Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget, 6(13), 11327–11341.PubMedPubMedCentralCrossRef
26.
Di Vizio, D., et al. (2012). Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. American Journal of Pathology, 181(5), 1573–1584.PubMedPubMedCentralCrossRef
27.
Ma, L., et al. (2015). Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Research, 25(1), 24–38.PubMedCrossRef
28.
Wright, P. K., et al. (2014). 17beta-estradiol regulates giant vesicle formation via estrogen receptor-alpha in human breast cancer cells. Oncotarget, 5(10), 3055–3065.PubMedPubMedCentralCrossRef
29.
Colombo, M., Raposo, G., & Thery, C. (2014). Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annual Review of Cell and Developmental Biology, 30, 255–289.PubMedCrossRef
30.
Kowal, J., Tkach, M., & Thery, C. (2014). Biogenesis and secretion of exosomes. Current Opinion in Cell Biology, 29, 116–125.PubMedCrossRef
31.
32.
33.
Takahashi, K., et al. (2014). Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio, 4, 458–467.PubMedPubMedCentralCrossRef
34.
Gusachenko, O. N., Zenkova, M. A., & Vlassov, V. V. (2013). Nucleic acids in exosomes: disease markers and intercellular communication molecules. Biochemistry (Mosc), 78(1), 1–7.CrossRef
35.
Gross, J. C., et al. (2012). Active Wnt proteins are secreted on exosomes. Nature Cell Biology, 14(10), 1036–1045.PubMedCrossRef
36.
Tsunemi, T., Hamada, K., & Krainc, D. (2014). ATP13A2/PARK9 regulates secretion of exosomes and alpha-synuclein. Journal of Neuroscience, 34(46), 15281–15287.PubMedPubMedCentralCrossRef
37.
Wei, J. X., et al. (2015). Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells. Hepatology, 61(4), 1284–1294.PubMedPubMedCentralCrossRef
38.
Savina, A., et al. (2003). Exosome release is regulated by a calcium-dependent mechanism in K562 cells. Journal of Biological Chemistry, 278(22), 20083–20090.PubMedCrossRef
39.
Li, J., et al. (2014). Beta-elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome. Lung Cancer, 86(2), 144–150.PubMedCrossRef
40.
Thompson, C. A., et al. (2013). Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. Journal of Biological Chemistry, 288(14), 10093–10099.PubMedPubMedCentralCrossRef
41.
Tian, T., et al. (2010). Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. Journal of Cellular Biochemistry, 111(2), 488–496.PubMedCrossRef
42.
Feng, D., et al. (2010). Cellular internalization of exosomes occurs through phagocytosis. Traffic, 11(5), 675–687.PubMedCrossRef
43.
44.
Szatanek, R., et al. (2015). Isolation of extracellular vesicles: determining the correct approach (review). International Journal of Molecular Medicine, 36(1), 11–17.PubMedPubMedCentral
45.
Xu, R., et al. (2016). Extracellular vesicle isolation and characterization: toward clinical application. Journal of Clinical Investigation, 126(4), 1152–1162.PubMedCrossRef
46.
Abramowicz, A., Widlak P., Pietrowska, M. (2016). Proteomic analysis of exosomal cargo: the challenge of high purity vesicle isolation. Molecular Biosystems.
47.
Batrakova, E. V., & Kim, M. S. (2015). Using exosomes, naturally-equipped nanocarriers, for drug delivery. Journal of Controlled Release, 219, 396–405.PubMedCrossRef
48.
Zeringer, E., et al. (2015). Strategies for isolation of exosomes. Cold Spring Harbor Protocols, 2015(4), 319–323.PubMedCrossRef
49.
Ko, J., Carpenter, E., & Issadore, D. (2016). Detection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices. Analyst, 141(2), 450–460.PubMedCrossRef
50.
Erdbrugger, U., & Lannigan, J. (2016). Analytical challenges of extracellular vesicle detection: a comparison of different techniques. Cytometry. Part A, 89(2), 123–134.CrossRef
51.
Pope, S. M. & Lasser, C. (2013). Toxoplasma gondii infection of fibroblasts causes the production of exosome-like vesicles containing a unique array of mRNA and miRNA transcripts compared to serum starvation. Journal of Extracellular Vesicles, 2.
52.
Jorgensen, M. M., Baek, R., & Varming, K. (2015). Potentials and capabilities of the extracellular vesicle (EV) array. Journal of Extracellular Vesicles, 4, 26048.PubMedCrossRef
53.
Vlassov, A. V., et al. (2012). Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochimica et Biophysica Acta, 1820(7), 940–948.PubMedCrossRef
54.
Liang, B., et al. (2013). Characterization and proteomic analysis of ovarian cancer-derived exosomes. Journal of Proteomics, 80, 171–182.PubMedCrossRef
55.
Shimbo, K., et al. (2014). Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochemical and Biophysical Research Communications, 445(2), 381–387.PubMedCrossRef
56.
Ventura, S., et al. (2015). CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-kappaB signaling. Oncogene.
57.
Zeelenberg, I. S., et al. (2008). Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Research, 68(4), 1228–1235.PubMedCrossRef
58.
Zeelenberg, I. S., et al. (2011). Antigen localization controls T cell-mediated tumor immunity. The Journal of Immunology, 187(3), 1281–1288.PubMedCrossRef
59.
Toda, Y., et al. (2015). Effective internalization of U251-MG-secreted exosomes into cancer cells and characterization of their lipid components. Biochemical and Biophysical Research Communications, 456(3), 768–773.PubMedCrossRef
60.
Mao, L., et al. (2016). Enterovirus 71 transmission by exosomes establishes a productive infection in human neuroblastoma cells. Virus Genes, 52(2), 189–194.PubMedCrossRef
61.
Atay, S., et al. (2014). Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proceedings of the National Academy of Sciences of the United States of America, 111(2), 711–716.PubMedCrossRef
62.
Tsuno, H., et al. (2016). Effects of methotrexate and salazosulfapyridine on protein profiles of exosomes derived from a human synovial sarcoma cell line of SW982. Proteomics Clinical Applications, 10(2), 164–171.PubMedCrossRef
63.
Sommer, G., et al. (2003). Gastrointestinal stromal tumors in a mouse model by targeted mutation of the kit receptor tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America, 100(11), 6706–6711.PubMedPubMedCentralCrossRef
64.
Rubin, B. P., et al. (2005). A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Research, 65(15), 6631–6639.PubMedCrossRef
65.
Saleem, S. N., & Abdel-Mageed, A. B. (2015). Tumor-derived exosomes in oncogenic reprogramming and cancer progression. Cellular and Molecular Life Sciences, 72(1), 1–10.PubMedCrossRef
66.
Endo-Munoz, L., et al. (2015). Progression of osteosarcoma from a non-metastatic to a metastatic phenotype is causally associated with activation of an autocrine and paracrine uPA Axis. PLoS One, 10(8), e0133592.PubMedPubMedCentralCrossRef
67.
Hakulinen, J., et al. (2008). Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. Journal of Cellular Biochemistry, 105(5), 1211–1218.PubMedCrossRef
68.
69.
Miller, I. V., et al. (2013). First identification of Ewing’s sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications. Biology of the Cell, 105(7), 289–303.PubMedCrossRef
70.
Remacle, A., Murphy, G., & Roghi, C. (2003). Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. Journal of Cell Science, 116(Pt 19), 3905–3916.PubMedCrossRef
71.
Thery, C., Zitvogel, L., & Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nature Reviews Immunology, 2(8), 569–579.PubMed
72.
Taylor, D. D., & Gercel-Taylor, C. (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecologic Oncology, 110(1), 13–21.PubMedCrossRef
73.
Liao, J., et al. (2016). Exosome-shuttling microRNA-21 promotes cell migration and invasion-targeting PDCD4 in esophageal cancer. International Journal of Oncology, 48(6), 2567–2579.PubMed
74.
Meng, X., et al. (2016). Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget, 7(13), 16923–16935.PubMedPubMedCentral
75.
Munagala, R., Aqil, F., Gupta, R.C. (2016). Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumour Biology.
76.
Berrondo, C., et al. (2016). Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One, 11(1), e0147236.PubMedPubMedCentralCrossRef
77.
Ruiz-Martinez, M., et al. (2016). YKT6 expression, exosome release, and survival in non-small cell lung cancer. Oncotarget.
78.
Rodriguez, M., et al. (2015). Exosomes enriched in stemness/metastatic-related mRNAS promote oncogenic potential in breast cancer. Oncotarget, 6(38), 40575–40587.PubMedPubMedCentral
79.
van den Boorn, J. G., et al. (2013). Exosomes as nucleic acid nanocarriers. Advanced Drug Delivery Reviews, 65(3), 331–335.PubMedCrossRef
80.
Hood, J. L., San, R. S., & Wickline, S. A. (2011). Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Research, 71(11), 3792–3801.PubMedCrossRef
81.
Alvarez-Erviti, L., et al. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 29(4), 341–345.PubMedCrossRef
82.
Sun, D., et al. (2010). A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Molecular Therapy, 18(9), 1606–1614.PubMedPubMedCentralCrossRef
83.
Zhuang, X., et al. (2011). Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Molecular Therapy, 19(10), 1769–1779.PubMedPubMedCentralCrossRef
84.
Wahlgren, J., et al. (2012). Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Research, 40(17), e130.PubMedPubMedCentralCrossRef
85.
Katsuda, T., et al. (2013). The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics, 13(10-11), 1637–1653.PubMedCrossRef
86.
Fang, Y., et al. (2015). Expression and clinical significance of cyclooxygenase-2 and microRNA-143 in osteosarcoma. Experimental and Therapeutic Medicine, 9(6), 2374–2378.PubMedPubMedCentral
87.
Zhou, J., et al. (2015). microRNA-143 is associated with the survival of ALDH1+CD133+ osteosarcoma cells and the chemoresistance of osteosarcoma. Experimental Biology and Medicine (Maywood, N.J.), 240(7), 867–875.CrossRef
88.
Arroyo, J. D., et al. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proceedings of the National Academy of Sciences of the United States of America, 108(12), 5003–5008.PubMedPubMedCentralCrossRef
Metadata
Title
The roles and implications of exosomes in sarcoma
Authors
Li Min
Jacson Shen
Chongqi Tu
Francis Hornicek
Zhenfeng Duan
Publication date
01-09-2016
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2016
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-016-9630-4

Other articles of this Issue 3/2016

Cancer and Metastasis Reviews 3/2016 Go to the issue

Retraction Note

Retraction Note: Targeted immune therapy of ovarian cancer

CLINICAL

Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives

CLINICAL

Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications

CLINICAL

Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature

NON-THEMATIC REVIEW

Calcium role in human carcinogenesis: a comprehensive analysis and critical review of literature

CLINICAL

Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits